Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB–IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB–IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial

Published:2022-10 Issue:10 Volume:23 Page:1274-1286
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

O’Brien Mary,Paz-Ares Luis,Marreaud Sandrine,Dafni Urania,Oselin Kersti,Havel Libor,Esteban Emilio,Isla Dolores,Martinez-Marti Alex,Faehling Martin,Tsuboi Masahiro,Lee Jong-Seok,Nakagawa Kazuhiko,Yang Jing,Samkari Ayman,Keller Steven M,Mauer Murielle,Jha Nitish,Stahel Rolf,Besse Benjamin,Peters Solange

Funder

Roche

AstraZeneca

British Microcirculation Society

Sanofi

Bayer

Meso Scale Diagnostics

Amgen

Takeda Pharmaceutical Company

Pfizer

Janssen Pharmaceuticals

GlaxoSmithKline

Merck Sharp and Dohme

Publisher

Elsevier BV

Subject

Oncology

Reference28 articles.

1. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up;Postmus;Ann Oncol,2017

2. Early and locally advanced non-small-cell lung cancer: an update of the ESMO Clinical Practice Guidelines focusing on diagnosis, staging, systemic and local therapy;Remon;Ann Oncol,2021

3. Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with locally-advanced unresectable non-small-cell lung cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS;Park;Ann Oncol,2020

4. Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data;Lancet,2010

5. Randomized phase III trial of vinorelbine plus cisplatin compared with observation in completely resected stage IB and II non-small-cell lung cancer: updated survival analysis of JBR-10;Butts;J Clin Oncol,2010

Cited by 333 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advances in clinical trials on perioperative immune checkpoint inhibitors for resectable non-small cell lung cancer: A comprehensive review;International Immunopharmacology;2024-11

2. The role of extensive lymph node dissection in the new grading system for lung adenocarcinoma;European Journal of Surgical Oncology;2024-10

3. Clinical multi-dimensional prognostic nomogram for predicting the efficacy of immunotherapy in NSCLC;Scientific Reports;2024-09-13

4. Identifying patients who benefit more from perioperative immunotherapy combinations for resectable non-small cell lung cancer based on clinical and molecular characteristics: a meta-analysis of randomized clinical trials;Clinical and Translational Oncology;2024-09-12

5. Harnessing the potential of genomic characterization of mutational profiles to improve early diagnosis of lung cancer;Expert Review of Molecular Diagnostics;2024-09-12

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3